20S Proteasome α6 Activators
The chemical class of 20S Proteasome α6 activators primarily consists of compounds that act as proteasome inhibitors. These compounds, while not directly activating the 20S Proteasome α6, influence its function and regulatory mechanisms through inhibition. By blocking the proteasomal degradation pathway, these inhibitors can lead to an accumulation of proteins within the cell, thereby triggering compensatory mechanisms that may affect the regulation and activity of the proteasome, including the 20S Proteasome α6 subunit.
Compounds such as MG-132, Bortezomib, Lactacystin, Carfilzomib, and Epoxomicin are notable for their ability to inhibit proteasome activity. This inhibition can lead to altered cellular responses, potentially affecting the regulation of the 20S Proteasome α6. For example, the inhibition of proteasomal activity by Bortezomib (Velcade) could trigger cellular stress responses that impact the function of the proteasome. Similarly, Carfilzomib's selective inhibition of the proteasome could lead to changes in proteasome dynamics and its interaction with various cellular proteins.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
A proteasome inhibitor that can indirectly affect the 20S Proteasome α6 by inhibiting proteasomal degradation, potentially leading to altered proteasome regulation and activity. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Another proteasome inhibitor, Bortezomib, may indirectly influence the 20S Proteasome α6 by disrupting normal proteasomal activity, leading to compensatory regulatory changes. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
An inhibitor of the proteasome, Lactacystin can indirectly affect the 20S Proteasome α6 by inhibiting its proteolytic activity, potentially influencing its regulation and function. | ||||||
Carfilzomib | 868540-17-4 | sc-396755 | 5 mg | $41.00 | ||
A selective proteasome inhibitor that could indirectly influence the 20S Proteasome α6 by modulating proteasome activity and regulatory pathways. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $137.00 $219.00 $449.00 $506.00 | 19 | |
A specific proteasome inhibitor, Epoxomicin, can indirectly affect the 20S Proteasome α6 by inhibiting proteasomal degradation processes. | ||||||
Oprozomib | 935888-69-0 | sc-477447 | 2.5 mg | $280.00 | ||
A proteasome inhibitor that might indirectly influence the 20S Proteasome α6 through its effect on proteasomal activity and cellular regulatory mechanisms. | ||||||
Ixazomib | 1072833-77-2 | sc-489103 sc-489103A | 10 mg 50 mg | $311.00 $719.00 | ||
A proteasome inhibitor that can have an indirect impact on the 20S Proteasome α6 by modulating proteasomal degradation pathways. | ||||||
Delanzomib, free base | 847499-27-8 | sc-396774 sc-396774A | 5 mg 10 mg | $160.00 $300.00 | ||
A proteasome inhibitor, Delanzomib may indirectly influence the 20S Proteasome α6 by affecting overall proteasome function. | ||||||